Posttransplant immunosuppression in highly sensitized patients

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• Kidney transplantation is often hindered by donor-specific anti-HLA antibodies (DSA).
• Desensitization protocols combining antibody removal (plasmapheresis/immunoadsorption) and immune modulation (IVIG, rituximab) enable transplantation across positive cross-matches.
• Despite short-term success, acute antibody-mediated rejection (AMR) persists in 20-30% of patients undergoing these protocols.

Purpose of the Study:

• To evaluate the effectiveness of current desensitization protocols in preventing early acute AMR after kidney transplantation.
• To identify optimal components of desensitization protocols, including antibody removal methods, IVIG dosing, induction therapy, and rituximab use.

Main Methods:

• Review of recent desensitization protocols for kidney transplantation.
• Analysis of patient and graft survival rates.
• Assessment of acute antibody-mediated rejection (AMR) incidence in relation to specific protocol elements.

Main Results:

• Desensitization protocols have improved short-term patient and graft survival by overcoming cross-match positivity.
• Acute AMR remains a significant barrier, occurring in 20-30% of patients.
• The optimal desensitization protocol, including specific agents like IVIG, plasmapheresis, and induction therapies, is not yet clearly defined.

Conclusions:

• While desensitization protocols facilitate kidney transplantation in sensitized individuals, they do not fully eliminate the risk of acute AMR.
• Further prospective, multicenter, randomized trials are essential to establish the ideal desensitization strategy for preventing early AMR.
• Optimizing protocols is crucial for improving long-term outcomes in kidney transplant recipients with pre-formed antibodies.